{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:10:52Z","timestamp":1782537052351,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2002,3,1]]},"DOI":"10.1038\/sj.jhh.1001352","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:39:12Z","timestamp":1031251152000},"page":"S93-S99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Angiotensin II receptor antagonists role in arterial hypertension"],"prefix":"10.1038","volume":"16","author":[{"given":"R","family":"Hern\u00e1ndez-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Sosa-Canache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Armas-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Armas-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,4,24]]},"reference":[{"key":"BF1001352_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/01.HYP.28.4.635","volume":"28","author":"GW Booz","year":"1996","unstructured":"Booz GW, Baker KM . Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy Hypertension 1996 28: 635\u2013640","journal-title":"Hypertension"},{"key":"BF1001352_CR2","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1161\/01.CIR.94.12.3087","volume":"94","author":"WR Ford","year":"1996","unstructured":"Ford WR, Clanachan AS, Jugdutt BL . Opposite effects of angiotensin AT1 and AT2 receptor antagonist on recovery of mechanical function after ischemia-reperfusion in isolated working rat heart Circulation 1996 94: 3087\u20133089","journal-title":"Circulation"},{"key":"BF1001352_CR3","first-page":"S1","volume":"12","author":"VJ Dzau","year":"1994","unstructured":"Dzau VJ, Mukoyama M, Pratt RE . Molecular biology of angiotensin receptors: target for drug research J Hypertens 1994 12: S1\u2013S5","journal-title":"J Hypertens"},{"key":"BF1001352_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0002-9343(76)90894-9","volume":"60","author":"DH Streeten","year":"1976","unstructured":"Streeten DH, Anderson GH Jr, Dalakos TH . Angiotensin II blockade: its clinical significance Am J Med 1976 60: 817\u2013824","journal-title":"Am J Med"},{"key":"BF1001352_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0033-0620(74)90024-3","volume":"17","author":"HR Brunner","year":"1974","unstructured":"Brunner HR, Gavras H, Laragh JH . Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation Prog Cardiovasc Dis 1974 17: 87\u201398","journal-title":"Prog Cardiovasc Dis"},{"key":"BF1001352_CR6","unstructured":"Furukawa Y, Kishimoto S, Hishikawa K . Tadeka Chemical Industries Ltd Hypotension imidazole-5 acetic acid derivatives. US Patent 4 355 o40, 20 July 1982."},{"key":"BF1001352_CR7","doi-asserted-by":"publisher","first-page":"209S","DOI":"10.1093\/ajh\/5.12.209S","volume":"5","author":"RR Wexeler","year":"1992","unstructured":"Wexeler RR et al. Rationale for the chemical development of angiotensin II receptor antagonist Am J Hypertens 1992 5: 209S\u2013220S","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR8","first-page":"711","volume":"252","author":"AT Chuiu","year":"1990","unstructured":"Chuiu AT et al. Non peptide angiotensin II receptor antagonists, VIII: characterization of functional antagonism displayed by Dup-753, an orally active antihypertensive agent J Pharmacol Exp Ther 1990 252: 711\u2013718","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1001352_CR9","first-page":"S37","volume":"12","author":"RT Gansevoor","year":"1994","unstructured":"Gansevoor RT et al. Effects of the angiotensin II antagonists losartan in hypertensivepatients with renal disease J Hypertens 1994 12: S37\u2013S42","journal-title":"J Hypertens"},{"key":"BF1001352_CR10","first-page":"1695","volume-title":"Hypertension: Pathophysiology; Diagnosis and Management. Second edition","author":"M de Gasparro","year":"1995","unstructured":"de Gasparro M, Bottari S, Levens NR . Characteristics of angiotensin II receptor and their role in cell and organ physiology In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology; Diagnosis and Management. Second edition Raven Press Thd: New York 1995 pp 1695\u20131720"},{"key":"BF1001352_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZH Israelli","year":"1992","unstructured":"Israelli ZH, Hall WD . Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitors therapy: a review of the literature and pathophysiology Ann Inter Med 1992 117: 234\u2013242","journal-title":"Ann Inter Med"},{"key":"BF1001352_CR12","doi-asserted-by":"publisher","first-page":"221S","DOI":"10.1093\/ajh\/5.12.221S","volume":"5","author":"PBMW Timmermans","year":"1992","unstructured":"Timmermans PBMW et al. Angiotensin II receptors and functional correlates Am J Hypertens 1992 5: 221S\u2013234S","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/sj.bjp.0702722","volume":"127","author":"RS Garcha","year":"1999","unstructured":"Garcha RS, Sever PS, Hugles AD . Action of AT1-receptor antagonist on angiotensin II-induced tone in human isolated subcutaneous resistance arteries Br J Pharmacol 1999 127: 1876\u20131882","journal-title":"Br J Pharmacol"},{"key":"BF1001352_CR14","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1161\/01.HYP.33.6.1406","volume":"33","author":"P Morsing","year":"1999","unstructured":"Morsing P et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin Hypertension 1999 33: 1406\u20131413","journal-title":"Hypertension"},{"key":"BF1001352_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","volume":"126","author":"PML Vanderheyden","year":"1999","unstructured":"Vanderheyden PML et al. Distinction between surmountable and insurmountable selective AT1-receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1-receptors Br J Pharmacol 1999 126: 1057\u20131065","journal-title":"Br J Pharmacol"},{"key":"BF1001352_CR16","first-page":"711","volume":"252","author":"AT Chiu","year":"1990","unstructured":"Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent J Pharmacol Exp Ther 1990 252: 711\u2013718","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1001352_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/00005344-199511000-00003","volume":"26","author":"C Corriu","year":"1995","unstructured":"Corriu C, Bernard S, Schott C, Stoclet JC . Effects of losartan on contractile responses of conductance and resistance arteries from rats J Cardiovasc Pharmacol 1995 26: 688\u2013692","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF1001352_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0006-2952(93)90420-2","volume":"46","author":"M Noda","year":"1993","unstructured":"Noda M et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist Biochem Pharmacol 1993 46: 311\u2013318","journal-title":"Biochem Pharmacol"},{"key":"BF1001352_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000139534","volume":"55","author":"E Ohlstein","year":"1997","unstructured":"Ohlstein E, Brooks D, Feuerstein G, Ruffolo R Jr . Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade Pharmacology 1997 55: 244\u2013251","journal-title":"Pharmacology"},{"key":"BF1001352_CR20","first-page":"S21","volume":"17 (Suppl\u20092)","author":"T Hedner","year":"1999","unstructured":"Hedner T . Management of hypertension: the advent of new angiotensin II receptor antagonist J Hypertens 1999 17 (Suppl\u20092): S21\u2013S25","journal-title":"J Hypertens"},{"key":"BF1001352_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/377744a0","volume":"377","author":"L Hein","year":"1995","unstructured":"Hein L et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice Nature 1995 377: 744\u2013747","journal-title":"Nature"},{"key":"BF1001352_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/377748a0","volume":"377","author":"T Ichiki","year":"1995","unstructured":"Ichiki T et al. Effects on blood pressure and exploratory behaviour of mice lack angiotensin II type-2 receptor Nature 1995 377: 748\u2013750","journal-title":"Nature"},{"key":"BF1001352_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1172\/JCI7886","volume":"104","author":"Y Tsutsumi","year":"1999","unstructured":"Tsutsumi Y et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation J Clin Invest 1999 104: 925\u2013935","journal-title":"J Clin Invest"},{"key":"BF1001352_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1043-2760(99)00205-2","volume":"11","author":"S Nouet","year":"2000","unstructured":"Nouet S, Nahmias C . Signal transduction from the angiotensin II AT2 receptor Trends Endocrinol Metab 2000 11: 1\u20136","journal-title":"Trends Endocrinol Metab"},{"key":"BF1001352_CR25","first-page":"5","volume":"1","author":"NK Hollenberg","year":"2000","unstructured":"Hollenberg NK, Sever PS . The past, present and future of hypertension management: a potential role for AT1-receptor antagonists JRAA 2000 1: 5\u201310","journal-title":"JRAA"},{"key":"BF1001352_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0006-291X(05)80983-0","volume":"351","author":"H Sasamura","year":"1992","unstructured":"Sasamura H et al. Cloning, characterization and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome Biochem Biophys Res Comun 1992 351: 253\u2013259","journal-title":"Biochem Biophys Res Comun"},{"key":"BF1001352_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/01.HYP.25.5.924","volume":"25","author":"M de Gasparo","year":"1995","unstructured":"de Gasparo M et al. Proposed update of angiotensin receptor nomenclature Hypertension 1995 25: 924\u2013927","journal-title":"Hypertension"},{"key":"BF1001352_CR28","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1161\/01.CIR.87.6.1816","volume":"87","author":"KK Griendling","year":"1993","unstructured":"Griendling KK, Murphy TJ, Alexander RW . Molecular biology of the renin-angiotensin system Circulation 1993 87: 1816\u20131824","journal-title":"Circulation"},{"key":"BF1001352_CR29","doi-asserted-by":"publisher","first-page":"62S","DOI":"10.1016\/S0895-7061(00)00274-0","volume":"13","author":"HM Siragy","year":"2000","unstructured":"Siragy HM . The role of the AT2 receptor in hypertension Am J Hypertens 2000 13: 62S\u201367S","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/01.HYP.15.6.823","volume":"15","author":"PC Wong","year":"1990","unstructured":"Wong PC et al. Non-peptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753 Hypertension 1990 15: 823\u2013834","journal-title":"Hypertension"},{"key":"BF1001352_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00003495-199754020-00009","volume":"54","author":"A Markahm","year":"1997","unstructured":"Markahm A, Goa KL . Valsartan. A review of its pharmacology and therapeutic use in essential hypertension Drug 1997 54: 299\u2013311","journal-title":"Drug"},{"key":"BF1001352_CR32","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/00004872-199715022-00005","volume":"15","author":"L Ruilope","year":"1997","unstructured":"Ruilope L . Human pharmacokinetic\/pharmaco-dynamic profile of irbesartan: a new potent angiotensin II receptor antagonist J Hypertens Suppl 1997 15: S15\u2013S20","journal-title":"J Hypertens Suppl"},{"key":"BF1001352_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1527-3466.1995.tb00305.x","volume":"13","author":"L Criscione","year":"1995","unstructured":"Criscione L et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist Cardiovasc Drug Res 1995 13: 230\u2013250","journal-title":"Cardiovasc Drug Res"},{"key":"BF1001352_CR34","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/00004872-199715066-00007","volume":"15","author":"MA Weber","year":"1997","unstructured":"Weber MA . Comparison of type I angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension J Hypertens 1997 15: S32\u2013S36","journal-title":"J Hypertens"},{"key":"BF1001352_CR35","first-page":"765","volume":"9","author":"JCN Chan","year":"1995","unstructured":"Chan JCN et al. A randomised, double blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared to felodipine ER in elderlypatients with mild to moderate hypertension J Hum Hypertens 1995 9: 765\u2013771","journal-title":"J Hum Hypertens"},{"key":"BF1001352_CR36","first-page":"82","volume":"2","author":"JM Mallion","year":"1996","unstructured":"Mallion JM, Goldberg AI . Global efficacy and tolerability of losartan, and angiotensin II subtype 1-receptor antagonist, in treatment of hypertension Blood Press Suppl 1996 2: 82\u201386","journal-title":"Blood Press Suppl"},{"key":"BF1001352_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1161\/01.HYP.26.1.112","volume":"26","author":"BA Soffer","year":"1995","unstructured":"Soffer BA et al. Effects of losartan on a blackground of hydrochlorothiazide inpatients with hypertension Hypertension 1995 26: 112\u2013117","journal-title":"Hypertension"},{"key":"BF1001352_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1185\/03007999909115169","volume":"15","author":"I Gavras","year":"1999","unstructured":"Gavras I, Gavras H . Effects of eprosartan versus enalapril in hypertensive patients on the renin angiotensin-aldosterone system and safety parameters; results from a 26 week, double-blind, multicenter study Curr Med Res Opin 1999 15: 15\u201324","journal-title":"Curr Med Res Opin"},{"key":"BF1001352_CR39","first-page":"S57","volume":"11 (Suppl\u20092)","author":"A Zanchetti","year":"1997","unstructured":"Zanchetti A . Candesartan cilexitil and enalapril are of equivalent efficacy inpatients with mild to moderate hypertension J Hum Hypertens 1997 11 (Suppl\u20092): S57\u2013S59","journal-title":"J Hum Hypertens"},{"key":"BF1001352_CR40","doi-asserted-by":"publisher","first-page":"318S","DOI":"10.1016\/S0895-7061(97)00386-5","volume":"10 (Suppl)","author":"HG Pouleur","year":"1997","unstructured":"Pouleur HG . Clinical overview of irbesartan: a new angiotensin II receptor antagonist Am J Hypertens 1997 10 (Suppl): 318S\u2013324S","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR41","doi-asserted-by":"publisher","first-page":"128A","DOI":"10.1016\/S0895-7061(97)89124-8","volume":"10","author":"C Ponticelli","year":"1997","unstructured":"Ponticelli C on behalf of the Eprosartan Study Group. Comparison of the efficacy of eprosartan and enalapril inpatients with severe hypertension Am J Hypertens 1997 10: 128A (Abstract)","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR42","first-page":"179","volume":"2","author":"JM Mallion","year":"1997","unstructured":"Mallion JM et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril Blood Press Monit 1997 2: 179\u2013184","journal-title":"Blood Press Monit"},{"key":"BF1001352_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00266358","volume":"42","author":"M Nakashima","year":"1992","unstructured":"Nakashima M, Uematsu T, Kosuge K, Kanamaru M . Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects Eur J Clin Pharmacol 1992 42: 333\u2013335","journal-title":"Eur J Clin Pharmacol"},{"key":"BF1001352_CR44","doi-asserted-by":"publisher","first-page":"18S","DOI":"10.1016\/S0895-7061(99)00250-2","volume":"13","author":"S Oparil","year":"2000","unstructured":"Oparil S . Newly emerging pharmacologic differences in angiotensin II receptor blockers Am J Hypertens 2000 13: 18S\u201324S","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR45","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0140-6736(73)92657-3","volume":"II","author":"Hr Brunner","year":"1973","unstructured":"Brunner Hr, Gavras H, Laragh JH, Keenan R . Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure Lancet 1973 II: 1045\u20131048","journal-title":"Lancet"},{"key":"BF1001352_CR46","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","volume":"14 (Suppl\u20091)","author":"ZH Israili","year":"2000","unstructured":"Israili ZH . Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 2000 14 (Suppl\u20091): S73\u2013S86","journal-title":"J Hum Hypertens"},{"key":"BF1001352_CR47","first-page":"S45","volume":"11 (Suppl\u20092)","author":"GG Belt","year":"1997","unstructured":"Belt GG et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers J Hum Hypertens 1997 11 (Suppl\u20092): S45\u2013S47","journal-title":"J Hum Hypertens"},{"key":"BF1001352_CR48","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0149-2918(00)88300-9","volume":"21","author":"AH Gradman","year":"1999","unstructured":"Gradman AH et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, inpatients with systemic hypertension, Eprosartan Study Group Clin Ther 1999 21: 442\u2013453","journal-title":"Clin Ther"},{"key":"BF1001352_CR49","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1046\/j.1523-1755.1998.06822.x","volume":"54 (Suppl\u200968)","author":"M Burnier","year":"1998","unstructured":"Burnier M, Brunner HR . Angiotensin II receptor antagonists in hypertension Kidney Intern 1998 54 (Suppl\u200968): S107\u2013S111","journal-title":"Kidney Intern"},{"key":"BF1001352_CR50","first-page":"621","volume-title":"Hypertension","author":"MC Ruddy","year":"1999","unstructured":"Ruddy MC, Kostis JB . Angiotensin II receptor antagonist In: Oparil S, Weber M (eds) Hypertension WB Saunders: Philadelphia 1999 Chapter 71 621\u2013636"},{"key":"BF1001352_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ajh\/5.2.95","volume":"5","author":"B Dahl\u00f6f","year":"1992","unstructured":"Dahl\u00f6f B, Pennert K, Hansson L . Reversal of left ventricular hypertrophy in hypertensivepatients: a metaanalysis of 109 treatment studies Am J Hypertens 1992 5: 95\u2013110","journal-title":"Am J Hypertens"},{"key":"BF1001352_CR52","first-page":"85","volume":"6","author":"JM Cruickshank","year":"1992","unstructured":"Cruickshank JM et al. Reversivility of left ventricular hypertrophy by differing types of antyhipertensive therapy J Hum Hypertens 1992 6: 85\u201390","journal-title":"J Hum Hypertens"},{"key":"BF1001352_CR53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0024-3205(92)90589-H","volume":"51","author":"K Mizuno","year":"1992","unstructured":"Mizuno K et al. Effects of losartan, non-peptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats Life Sci 1992 51: 367\u2013374","journal-title":"Life Sci"},{"key":"BF1001352_CR54","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/01.HYP.20.6.746","volume":"20","author":"B Bunkerburg","year":"1992","unstructured":"Bunkerburg B et al. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats Hypertension 1992 20: 746\u2013754","journal-title":"Hypertension"},{"key":"BF1001352_CR55","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1161\/01.CIR.98.19.2037","volume":"98","author":"PA Th\u00fcrmann","year":"1998","unstructured":"Th\u00fcrmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy inpatients with essential hypertension Circulation 1998 98: 2037\u20132042","journal-title":"Circulation"},{"key":"BF1001352_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0002-9149(99)80413-5","volume":"75","author":"AI Golbert","year":"1995","unstructured":"Golbert AI, Dunlay MC, Sweet CS . Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochrothiazide, atenolol, felodipine AR and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension Am J Cardiol 1995 75: 793\u2013795","journal-title":"Am J Cardiol"},{"key":"BF1001352_CR57","unstructured":"Physician Desk Reference 52 edition Medical Economics Data 1999"},{"key":"BF1001352_CR58","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/j.1552-4604.1997.tb04788.x","volume":"37","author":"P Chan","year":"1997","unstructured":"Chan P et al. Double-blind comparison of losartan, lisinopril and metolazone in elderly hypertensivepatients with previous angiotensin-converting enzyme inhibitor-induced cough J Clin Pharmacol 1997 37: 253\u2013257","journal-title":"J Clin Pharmacol"},{"key":"BF1001352_CR59","first-page":"197","volume":"63","author":"G Stettin","year":"1998","unstructured":"Stettin G et al. One-year persistency and compliance with 5 major classes of antihypertensive therapy (abstract) Clin Pharmacol Ther 1998 63: 197","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001352","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:09:48Z","timestamp":1647536988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":59,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["BF1001352"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001352","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,1]]},"assertion":[{"value":"24 April 2002","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}